Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells

PLoS One. 2015 May 26;10(5):e0126526. doi: 10.1371/journal.pone.0126526. eCollection 2015.

Abstract

Ezrin belongs to the ERM (ezrin-radixin-moesin) protein family and has been demonstrated to regulate early steps of Fas receptor signalling in lymphoid cells, but its contribution to TRAIL-induced cell death regulation in adherent cancer cells remains unknown. In this study we report that regulation of FasL and TRAIL-induced cell death by ezrin is cell type dependant. Ezrin is a positive regulator of apoptosis in T-lymphoma cell line Jurkat, but a negative regulator in colon cancer cells. Using ezrin phosphorylation or actin-binding mutants, we provide evidence that negative regulation of death receptor-induced apoptosis by ezrin occurs in a cytoskeleton- and DISC-independent manner, in colon cancer cells. Remarkably, inhibition of apoptosis induced by these ligands was found to be tightly associated with regulation of ezrin phosphorylation on serine 66, the tumor suppressor gene WWOX and activation of PKA. Deficiency in WWOX expression in the liver cancer SK-HEP1 or the pancreatic Mia PaCa-2 cell lines as well as WWOX silencing or modulation of PKA activation by pharmacological regulators, in the colon cancer cell line SW480, abrogated regulation of TRAIL signalling by ezrin. Altogether our results show that death receptor pro-apoptotic signalling regulation by ezrin can occur downstream of the DISC in colon cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis* / drug effects
  • Cell Line, Tumor
  • Colonic Neoplasms / metabolism*
  • Colonic Neoplasms / pathology*
  • Cytoskeletal Proteins / metabolism*
  • Humans
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Oxidoreductases / metabolism
  • Phosphorylation / drug effects
  • Phosphoserine / metabolism
  • Receptors, Death Domain / metabolism*
  • Signal Transduction* / drug effects
  • TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • Tumor Suppressor Proteins / metabolism
  • WW Domain-Containing Oxidoreductase
  • fas Receptor / metabolism

Substances

  • Cytoskeletal Proteins
  • FAS protein, human
  • Receptors, Death Domain
  • TNF-Related Apoptosis-Inducing Ligand
  • Tumor Suppressor Proteins
  • ezrin
  • fas Receptor
  • Phosphoserine
  • Oxidoreductases
  • WW Domain-Containing Oxidoreductase
  • WWOX protein, human

Grants and funding

This work was supported by grants from the European Community (ApopTrain Marie Curie RTN), the program “Investissements d’Avenir” with reference ANR-11-LABX-0021-01-LipSTIC Labex, the University of Bourgogne, the Conseil Régional de Bourgogne, the INCa (Institut National du Cancer, POLYNOM-174), the Cancéropôle Grand-Est, the Ligue Nationale contre le Cancer, ARC (Association pour la Recherche sur le Cancer), and Ministry of Research and Education. EI, SS, LZ and AM were supported by fellowships from the Marie Curie RTN, INCa, CAPES (N° BEX4938/14-3) and the Ligue Nationale Contre le Cancer, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.